Stockreport

Immunic Highlights 2024 Accomplishments and Upcoming Milestones [Yahoo! Finance]

Immunic, Inc.  (IMUX) 
PDF – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track t [Read more]